Samuel Seltzer, MD
Ophthalmology · Florence, SCNPI 1053379107
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 75.4% of it on its own, with 10 other manufacturers making up the rest.
Across 55 payments — averaging $50.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Rxsight Inc$206
- Johnson & Johnson Surgical Vision, Inc.$124
- Mallinckrodt Hospital Products Inc.$109
- Sight Sciences, Inc.$88
- Novartis$38
- plus $111 from 5 others
Across 48 payments — averaging $667.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$25K
- AbbVie$7K
What the payments were for
- Speaking & faculty fees$391%
- Food & beverage$2,59894%
- Education$1164%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 38 | $2,075 |
| Rxsight Inc | 5 | $206 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $124 |
| Mallinckrodt Hospital Products Inc. | 2 | $109 |
| Sight Sciences, Inc. | 1 | $88 |
| Novartis | 2 | $38 |
| Omeros Corporation | 2 | $29 |
| Thea Pharma Inc. | 1 | $25 |
| Ocular Therapeutix, Inc. | 1 | $20 |
| Harrow Eye, LLC | 1 | $20 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$788
- AcrySof IQ VIVITY IOL$242
- AcrySof IQ PanOptix$142
- Tecnis IOL$124
How this compares
$2,753 in reported general payments places this provider in the 60th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 688 | $38,680 |
| Diclofenac Sodium | 673 | $10,568 |
| ProlensaBromfenac Sodium | 25 | $9,275 |
| Latanoprost | 126 | $1,487 |
| Ketorolac Tromethamine | 36 | $1,142 |
| Timolol Maleate | 61 | $1,037 |
| Brimonidine Tartrate | 40 | $713 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $473 |
| Ofloxacin | 18 | $299 |
| Dorzolamide Hcl | 18 | $285 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Florence
- Howard GreeneFlorence$8K
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
- Joseph BishopHilton Head Island$136K
- Erik HappMt Pleasant$124K
- Matthew ClaryColumbia$119K
- Kunal KanitkarLexington$83K
- Carl SloanMyrtle Beach$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.